Scilex Holding (SCLX) Cash from Operations (QoQ) (2020 - 2026)
Scilex Holding (SCLX) Cash from Operations (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.67% |
| Dec 31, 2025 | -312.11% |
| Sep 30, 2025 | 16.92% |
| Jun 30, 2025 | 17.36% |
| Mar 31, 2025 | 137.06% |
| Dec 31, 2024 | -50.44% |
| Sep 30, 2024 | 121.25% |
| Jun 30, 2024 | -75.39% |
| Mar 31, 2024 | 274.23% |
| Dec 31, 2023 | -191.36% |
| Sep 30, 2023 | 143.79% |
| Jun 30, 2023 | -73.98% |
| Mar 31, 2023 | -968.14% |
| Dec 31, 2022 | -128.62% |
| Sep 30, 2022 | 120.54% |
| Jun 30, 2022 | -14.95% |
| Mar 31, 2022 | 61.63% |
| Dec 31, 2021 | -19,600.37% |
| Sep 30, 2021 | 74.26% |
| Jun 30, 2021 | -11.59% |